Skip to content

Sarepta Therapeutics, Inc. SRPT Treasury Stock, Value

Treasury Stock, Value at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$60K-3.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$10M+32.2%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s treasury stock, value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s treasury stock, value?
Sarepta Therapeutics, Inc. (SRPT) reported treasury stock, value of $25.26M in Q1 2026.
What does treasury stock, value mean?
This represents the cost of common shares that the company has repurchased from the open market and holds in its treasury. Treasury stock reduces total shareholders' equity and is often used for employee stock compensation plans or to return capital to shareholders. It is recorded as a contra-equity account.